SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Prohibition sign. Halftone hands cross their fingers in a no entry sign. Refusal, stop gesture. Rejection sign. Warning concept. Newspaper collage
FDA
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and well-controlled studies. The FDA previously turned the candidate away in November 2023 and April 2025.
March 17, 2026
 · 
2 min read
 · 
Heather McKenzie
Marty Makary speaks at a podium, with President Trump, RFK Jr., and Mehmet Oz in the background.
FDA
What the Leucovorin Approval Signals—or Doesn’t—About the FDA’s Rare Disease Stance
Although FDA Commissioner Marty Makary promised “an exciting treatment” for autism, what the agency delivered was a label expansion for leucovorin to treat the ultrarare cerebral folate deficiency. The regulatory process, which relied on a literature review rather than new evidence, stands in contrast to recent rare disease rejections in which the FDA cited a need for more rigorous evidence.
March 17, 2026
 · 
5 min read
 · 
Shawna Williams
Cambridge, USA - 8 July 2025. Pfizer office entrance with logo on a modern glass building, surrounded by greenery.
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
 · 
1 min read
 · 
Annalee Armstrong
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Obesity
Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities
The Phase 3 EMANATE study is a basket trial looking at the efficacy of Rhythm Pharmaceuticals’ injectable obesity drug across four types of obesities driven by specific genetic mutations.
March 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.
March 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Creative photo collage or modern art collage featuring symbols of law and justice. Hand holding a gavel and scales of justice with books about law.
Legal
Kennedy’s Vaccine Policy Overhaul Stymied by Federal Judge
A Massachusetts judge called Kennedy’s efforts to reform the CDC’s vaccines advisory panel a “procedural failure,” adding that the new committee members do not “comport with governing law.”
March 17, 2026
 · 
3 min read
 · 
Tristan Manalac
Symbolic image: Life as a hurdling - person faces challenges
Insights
AI Drug Discovery Platforms Face New Investor Bar
In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
March 17, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Rare diseases
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal
With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding to the pressure, the company suffered a setback Monday when it halted two studies of Voxzogo in other growth-related conditions following multiple cases of hip injuries in other trials of the drug.
March 16, 2026
 · 
2 min read
 · 
Heather McKenzie
Art collage with male hand and graphs. Concept of business, finance, economy, professionalism and success. Symbolism and surrealism. Copy space.
Obesity
Structure Climbs on ‘Highly Competitive’ Profile for Weight Loss Pill
Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later this year.
March 16, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS